Recruiting studies: Adjuvant Therapy For Bladder Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
Phase 2 · 1 location(s) · Changhai Hospital · NCT07307456 Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
Phase N/A · 1 location(s) · Zhilong Dong · NCT07424560 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · 499 location(s) · National Cancer Institute (NCI) · NCT05987241 Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT06586255 PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06696742

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.